Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

IsoRay stock price, quote, forecast and news

ISR
US46489V1044
A0MQNM

Price

0.28
Today +/-
+0
Today %
+0 %
P

IsoRay stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IsoRay stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IsoRay stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IsoRay stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IsoRay's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IsoRay Stock Price History

DateIsoRay Price
10/9/20230.28 undefined
10/6/20230.30 undefined

IsoRay Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IsoRay, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IsoRay from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IsoRay’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IsoRay. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IsoRay’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IsoRay’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IsoRay’s growth potential.

IsoRay Revenue, EBIT and net profit per share

DateIsoRay RevenueIsoRay EBITIsoRay Net Income
2026e38.51 M undefined5.99 M undefined4.75 M undefined
2025e32.62 M undefined6.14 M undefined5.19 M undefined
2024e24.2 M undefined6.36 M undefined-4.17 M undefined
2023e16.21 M undefined-7.37 M undefined-7.18 M undefined
202210.8 M undefined-7.39 M undefined-7.27 M undefined
202110.05 M undefined-3.44 M undefined-3.39 M undefined
20209.68 M undefined-3.48 M undefined-3.46 M undefined
20197.31 M undefined-5.28 M undefined-5.16 M undefined
20185.92 M undefined-6.73 M undefined-6.71 M undefined
20174.76 M undefined-6.31 M undefined-6.17 M undefined
20164.77 M undefined-5.08 M undefined-4.72 M undefined
20154.61 M undefined-4.34 M undefined-3.69 M undefined
20144.22 M undefined-4.59 M undefined-6.7 M undefined
20134.53 M undefined-4.07 M undefined-3.87 M undefined
20125.07 M undefined-3.6 M undefined-3.5 M undefined
20115.24 M undefined-2.96 M undefined-2.85 M undefined
20105.29 M undefined-4.01 M undefined-4.04 M undefined
20095.42 M undefined-6.47 M undefined-6.16 M undefined
20087.16 M undefined-8.8 M undefined-8.56 M undefined
20075.74 M undefined-9.7 M undefined-9.61 M undefined
20061.99 M undefined-7.2 M undefined-8.22 M undefined
20050 undefined-30,000 undefined-30,000 undefined
20040 undefined-10,000 undefined80,000 undefined
20030 undefined-20,000 undefined-60,000 undefined

IsoRay Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
0000157555544444579101016243238
-----400.0040.00-28.57----20.00----25.0040.0028.5711.11-60.0050.0033.3318.75
-----100.00----20.00------20.0042.8655.5650.0040.00----
0000-100001000000135540000
0000-7-9-8-6-4-2-3-4-4-4-5-6-6-5-3-3-7-7665
-----700.00-180.00-114.29-120.00-80.00-40.00-60.00-100.00-100.00-100.00-125.00-150.00-120.00-71.43-33.33-30.00-70.00-43.7525.0018.7513.16
0000-8-9-8-6-4-2-3-3-6-3-4-6-6-5-3-3-7-7-454
-----12.50-11.11-25.00-33.33-50.0050.00-100.00-50.0033.3350.00--16.67-40.00-133.33--42.86-225.00-20.00
9.8924.152.362.4312.0517.8323.0322.9422.9625.1328.6234.4242.6854.8855.0155.0255.1667.0467.6103.84141.990000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The IsoRay Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IsoRay is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                         
0000.032.2119.38.554.671.682.112.672.917.6814.5912.398.973.435.332.3963.8355.89
00000.61.091.020.750.90.790.870.920.911.050.60.731.191.152.042.011.61
0000000004300206019.620.11674186313217
00000.160.880.90.790.680.750.440.410.360.40.330.320.490.530.650.981.4
0000160460270150260140150200210263.6303.73204294219395449418
0000.033.1321.7310.746.363.524.224.134.4519.2216.3313.6310.295.457.325.5167.359.33
00001.643.676.044.893.963.212.421.681.020.570.581.051.311.612.742.732.49
0000000000005.45.112.97000000
000000000000000000000
0000290290480250220200200220260245.03150.53230198162138130107
000000000000000000000
00000.590.390.560.250.250.250.750.710.650.760.770.690.50.340.320.262.52
00002.524.357.085.394.433.663.372.617.336.684.471.982.012.113.193.115.11
0000.035.6526.0817.8211.757.957.887.57.0626.552318.112.277.459.428.770.4264.44
                                         
106070020202020203030305055.0355.0755566769142142
6.196.726.817.3116.4245.8547.4747.8248.0851.1854.0357.4381.9682.4782.7983.1584.3292.1193.59158.59159.73
-7.28-7.34-7.27-7.3-13.55-23.15-31.71-37.87-41.9-44.75-48.23-52.09-58.05-61.73-66.44-72.6-79.35-84.49-87.94-91.33-98.6
000000000000000000000
000000000000000000000
-1.08-0.56-0.390.012.8922.7215.789.976.26.465.835.3723.9620.7916.410.65.037.685.7267.4161.28
0000.020.581.950.750.70.40.370.390.430.570.50.610.631.390.680.650.730.97
0.690.470.3900.630.460.350.190.560.40.260.360.580.590.480.480.440.440.921.071.3
00000160000000000000000
000000000000000000000
400100006902409016050000000000000
1.090.570.390.021.92.811.191.051.010.770.650.791.151.091.091.111.841.121.581.82.27
0000800550350180130000000000000
000000000000000000000
00000.0700.510.550.610.661.040.91.441.130.610.560.590.621.41.210.9
00000.870.550.860.730.740.661.040.91.441.130.610.560.590.621.41.210.9
1.090.570.390.022.773.362.051.781.751.431.691.692.592.221.71.672.431.742.983.013.16
0.010.0100.035.6626.0817.8311.757.957.897.527.0626.5523.0118.112.277.469.428.770.4264.44
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IsoRay provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IsoRay's financial health and stability.

Assets

IsoRay's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IsoRay must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IsoRay after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IsoRay's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)

IsoRay stock margins

The IsoRay margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IsoRay. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IsoRay.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IsoRay's sales revenue. A higher gross margin percentage indicates that the IsoRay retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IsoRay's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IsoRay's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IsoRay's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IsoRay. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IsoRay's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IsoRay Margin History

IsoRay Gross marginIsoRay Profit marginIsoRay EBIT marginIsoRay Profit margin
2026e42.76 %15.56 %12.32 %
2025e42.76 %18.83 %15.92 %
2024e42.76 %26.29 %-17.24 %
2023e42.76 %-45.5 %-44.28 %
202242.76 %-68.47 %-67.36 %
202150.94 %-34.19 %-33.72 %
202052.93 %-35.91 %-35.71 %
201941.66 %-72.16 %-70.48 %
201831.1 %-113.61 %-113.3 %
201717.6 %-132.47 %-129.66 %
20162.71 %-106.56 %-99 %
20153.63 %-94.13 %-80.14 %
2014-4.74 %-108.77 %-158.77 %
20133.31 %-89.85 %-85.43 %
201213.81 %-71.01 %-69.03 %
201122.14 %-56.49 %-54.39 %
201013.8 %-75.8 %-76.37 %
2009-6.46 %-119.37 %-113.65 %
2008-2.09 %-122.91 %-119.55 %
2007-1.05 %-168.99 %-167.42 %
2006-91.46 %-361.81 %-413.07 %
200542.76 %0 %0 %
200442.76 %0 %0 %
200342.76 %0 %0 %

IsoRay Stock Sales Revenue, EBIT, Earnings per Share

The IsoRay earnings per share therefore indicates how much revenue IsoRay has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IsoRay earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IsoRay's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IsoRay’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IsoRay's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IsoRay Revenue, EBIT and net profit per share

DateIsoRay Sales per ShareIsoRay EBIT per shareIsoRay Earnings per Share
2026e0.27 undefined0 undefined0.03 undefined
2025e0.23 undefined0 undefined0.04 undefined
2024e0.17 undefined0 undefined-0.03 undefined
2023e0.11 undefined0 undefined-0.05 undefined
20220.08 undefined-0.05 undefined-0.05 undefined
20210.1 undefined-0.03 undefined-0.03 undefined
20200.14 undefined-0.05 undefined-0.05 undefined
20190.11 undefined-0.08 undefined-0.08 undefined
20180.11 undefined-0.12 undefined-0.12 undefined
20170.09 undefined-0.11 undefined-0.11 undefined
20160.09 undefined-0.09 undefined-0.09 undefined
20150.08 undefined-0.08 undefined-0.07 undefined
20140.1 undefined-0.11 undefined-0.16 undefined
20130.13 undefined-0.12 undefined-0.11 undefined
20120.18 undefined-0.13 undefined-0.12 undefined
20110.21 undefined-0.12 undefined-0.11 undefined
20100.23 undefined-0.17 undefined-0.18 undefined
20090.24 undefined-0.28 undefined-0.27 undefined
20080.31 undefined-0.38 undefined-0.37 undefined
20070.32 undefined-0.54 undefined-0.54 undefined
20060.17 undefined-0.6 undefined-0.68 undefined
20050 undefined-0.01 undefined-0.01 undefined
20040 undefined-0 undefined0.03 undefined
20030 undefined-0 undefined-0 undefined

IsoRay business model

The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.com.

IsoRay SWOT Analysis

Strengths

IsoRay Inc. possesses several strengths that contribute to its competitive advantage in the market:

  • Unique and innovative proprietary technology
  • Strong intellectual property portfolio
  • Established brand reputation
  • High-quality products
  • Experienced leadership team
  • Efficient production processes

Weaknesses

Despite its strengths, IsoRay Inc. also faces certain weaknesses that can hinder its growth and performance:

  • Dependency on a limited product portfolio
  • Relatively small market share compared to competitors
  • Financial constraints affecting research and development
  • Increased competition in the industry
  • Limited geographic presence

Opportunities

IsoRay Inc. has opportunities that can be exploited to further enhance its market position and profitability:

  • Growing demand for cancer treatment solutions
  • Expansion into new geographic regions
  • Collaboration and partnerships with healthcare providers
  • Advancements in technology to improve product offerings
  • Increasing healthcare expenditures worldwide

Threats

IsoRay Inc. faces several threats that could impact its business and sustainability in the market:

  • Strict regulations and compliance requirements
  • Intense competition from larger, well-established companies
  • Economic downturns affecting healthcare spending
  • Emerging alternative treatment methods
  • Volatility in pricing and reimbursement policies

IsoRay Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IsoRay historical P/E ratio, EBIT, and P/S ratio.

IsoRay shares outstanding

The number of shares was IsoRay in 2023 — This indicates how many shares 141.987 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IsoRay earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IsoRay's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IsoRay’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IsoRay's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IsoRay Stock splits

In IsoRay's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for IsoRay.

IsoRay list of shareholders

%
Name
Stocks
Change
Date
4.25564 % The Vanguard Group, Inc.6,047,81506/30/2022
2.05083 % Perkins Capital Management, Inc.2,914,500116,0006/30/2022
1.72071 % BlackRock Institutional Trust Company, N.A.2,445,3536,1356/30/2022
0.79592 % Geode Capital Management, L.L.C.1,131,10512,0356/30/2022
0.62986 % Woods (Lori A.)895,114304,5389/23/2021
0.54559 % Taylor & Morgan Asset Management, LLC775,354225,3546/30/2022
0.47089 % Bard Associates Inc.669,20006/30/2022
0.38956 % State Street Global Advisors (US)553,61906/30/2022
0.38702 % Venator Capital Management Ltd.550,000550,0006/30/2022
0.26535 % Renaissance Technologies LLC377,092-40,2236/30/2022
1
2
3
4
5
...
10

IsoRay Executives and Management Board

Ms. Lori Woods59
IsoRay Chief Executive Officer, Director
Compensation 371,195
Mrs. Jennifer Streeter52
IsoRay Chief Operating Officer, Vice President - Human Resources
Compensation 266,349
Mr. William Cavanagh56
IsoRay Chief Research and Development Officer
Compensation 253,339
Mr. Jonathan Hunt54
IsoRay Chief Financial Officer, Co-Principal Financial Officer (since 2019)
Compensation 166,019
Mr. Alan Hoffmann60
IsoRay Independent Director
Compensation 46,500
1
2

IsoRay Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
FedEx Stock
FedEx
SupplierCustomer-0,300,140,700,630,780,17
1

Most common questions regarding IsoRay

What values and corporate philosophy does IsoRay represent?

IsoRay Inc represents a strong commitment to improving the lives of cancer patients through its innovative products and solutions. The company's corporate philosophy revolves around delivering cutting-edge brachytherapy solutions that offer precise, targeted cancer treatment. IsoRay Inc values integrity, quality, and teamwork, striving to provide physicians and patients with reliable and effective solutions for various cancer types. With its pioneering Cesium-131 brachytherapy seeds, IsoRay Inc aims to revolutionize cancer therapy by providing superior outcomes and enhancing patients' quality of life. The company's dedication to technological advancements and patient-centric approach sets it apart in the healthcare industry.

In which countries and regions is IsoRay primarily present?

IsoRay Inc is primarily present in the United States.

What significant milestones has the company IsoRay achieved?

IsoRay Inc has achieved several significant milestones. The company specializes in innovative brachytherapy solutions for the treatment of cancer. Over the years, IsoRay Inc has successfully developed and commercialized its proprietary Cesium-131 (Cs-131) brachytherapy seeds, which have been widely recognized for their effectiveness in treating prostate, brain, lung, and other cancers. IsoRay Inc has also obtained FDA clearance for its novel GammaTile® Therapy, a radiation treatment for brain tumors. Moreover, the company has expanded its global presence, establishing partnerships with healthcare providers and achieving regulatory approvals in multiple countries. These milestones highlight IsoRay Inc's dedication to improving cancer care through cutting-edge technologies and expanding its reach in the healthcare industry.

What is the history and background of the company IsoRay?

IsoRay Inc is a renowned company specializing in personalized internal radiation therapy products. Established in 1998, IsoRay has since become a prominent player in the medical industry. The company is dedicated to providing innovative solutions for cancer treatment, particularly in the field of brachytherapy. IsoRay Inc has developed and commercialized Cesium-131, a radiation isotope that offers superior treatment outcomes for various cancer types. With a steadfast commitment to improving patients' quality of life, IsoRay continues to lead the way in radiation therapy advancements. With its rich history and expertise, IsoRay Inc remains at the forefront of the fight against cancer.

Who are the main competitors of IsoRay in the market?

Some of the main competitors of IsoRay Inc in the market include Varian Medical Systems, Eckert & Ziegler BEBIG, and Elekta AB.

In which industries is IsoRay primarily active?

IsoRay Inc is primarily active in the medical industry. With a focus on innovative advancements in brachytherapy, IsoRay Inc specializes in the production and sale of personalized cancer treatment solutions. This dynamic company operates within the healthcare sector, providing cutting-edge IsoRay Cesium-131 seed technology for the treatment of various forms of cancer. Through its industry expertise and dedication to improving patient outcomes, IsoRay Inc has gained recognition as a leading player in the medical field.

What is the business model of IsoRay?

IsoRay Inc is a renowned company that specializes in the development and commercialization of innovative solutions for the treatment of cancer and other diseases. Its business model revolves around the research, production, and distribution of brachytherapy products. These products involve the use of radiation therapy, specifically Cesium-131, to target and destroy cancer cells while minimizing damage to healthy tissues. By offering safe and effective treatment options, IsoRay Inc aims to improve patient outcomes and enhance the quality of life for individuals battling cancer. With its focus on cutting-edge brachytherapy technologies, IsoRay Inc continues to advance the field of oncology and contribute to the fight against cancer.

What is the P/E ratio of IsoRay 2024?

The IsoRay P/E ratio is -9.53.

What is the P/S ratio of IsoRay 2024?

The IsoRay P/S ratio is 1.64.

What is the AlleAktien quality score of IsoRay?

The AlleAktien quality score for IsoRay is 6/10.

What is the revenue of IsoRay 2024?

The expected IsoRay revenue is 24.2 M USD.

How high is the profit of IsoRay 2024?

The expected IsoRay profit is -4.17 M USD.

What is the business model of IsoRay

IsoRay Inc is a medical technology company based in Richland, Washington, USA. The company is the leading provider of innovative brachytherapy products. Brachytherapy is a method used in the treatment of cancer, where the radioactive source is directly placed into the cancer cells. IsoRay operates in two main business segments. The first segment focuses on the sale of Prostate Seed Implants. These implants are used in the treatment of prostate cancer and are IsoRay's flagship product. Implants provide better treatment by delivering a high dose of radiation directly to the cancer cells while protecting the surrounding organs and tissues. The implants consist of small radiation sources that are placed into the prostate. Brachytherapy is an alternative to other treatments such as surgery or radiation therapy. The implant is inserted by specially trained surgeons, and IsoRay provides support and training for medical personnel. IsoRay's second business segment focuses on the development and marketing of radioactive plaques and radiation sources. These products can be used in the treatment of brain cancer, lung cancer, and other types of cancer. The radioactive plaques are surgically implanted and deliver radiation directly to the tumor. The radiation sources are used in brachytherapy to ensure precise treatment. IsoRay has established itself as a market leader in brachytherapy products. The company aims to provide its customers with precise treatments while preserving the surrounding tissues and organs. The company collaborates closely with the medical community and research institutions to continually improve its products and technologies. IsoRay also has a number of patents that protect the effectiveness of its products and increase competitiveness. IsoRay operates an effective marketing and distribution program to make its products known in the medical community. The company works with healthcare facilities and offers training and support to ensure that its products are well understood and used. IsoRay also utilizes online marketing to create direct demand among patients and healthcare professionals. IsoRay's business model focuses on the development and marketing of brachytherapy products, particularly Prostate Seed Implants. The company is a market leader in this field and continues to strive to develop innovative technologies and provide precise, gentle treatments. The close collaboration with the medical community, the marketing and distribution initiatives, and the patent applications have helped the company grow in this lucrative market.

What is the IsoRay dividend?

IsoRay pays a dividend of 0 USD distributed over payouts per year.

How often does IsoRay pay dividends?

The dividend cannot currently be calculated for IsoRay or the company does not pay out a dividend.

What is the IsoRay ISIN?

The ISIN of IsoRay is US46489V1044.

What is the IsoRay WKN?

The WKN of IsoRay is A0MQNM.

What is the IsoRay ticker?

The ticker of IsoRay is ISR.

How much dividend does IsoRay pay?

Over the past 12 months, IsoRay paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IsoRay is expected to pay a dividend of 0 USD.

What is the dividend yield of IsoRay?

The current dividend yield of IsoRay is .

When does IsoRay pay dividends?

IsoRay pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IsoRay?

IsoRay paid dividends every year for the past 0 years.

What is the dividend of IsoRay?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IsoRay located?

IsoRay is assigned to the 'Health' sector.

Wann musste ich die Aktien von IsoRay kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IsoRay from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did IsoRay pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of IsoRay in the year 2023?

In the year 2023, IsoRay distributed 0 USD as dividends.

In which currency does IsoRay pay out the dividend?

The dividends of IsoRay are distributed in USD.

All fundamentals about IsoRay

Our stock analysis for IsoRay Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IsoRay Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.